The Health Insurance Review and Assessment Service (HIRA) announced that drug prices will be adjusted in the second half of next year by reevaluating foreign drug price comparisons.

This year, an announcement about reevaluation will be made, and the HIRA will conduct the evaluation in the first half of next year.

On August 20th, President of the HIRA Jung-Gu Kang announced this during a meeting with journalists.

Kang said, "We have had ten meetings so far to discuss about detailed criteria related to the reevaluation of foreign drug price comparisons with the pharmaceutical industry." Kang explained, "Based on discussions, the final plan for reevaluation will be